Complete financial analysis of Renalytix Plc (RTNXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Renalytix Plc, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Toumei Co.,Ltd. (4439.T) Income Statement Analysis – Financial Results
- PT FAP Agri Tbk (FAPA.JK) Income Statement Analysis – Financial Results
- Zhejiang Jianfeng Group Co., Ltd. (600668.SS) Income Statement Analysis – Financial Results
- Jiangsu Tongda Power Technology Co.,Ltd. (002576.SZ) Income Statement Analysis – Financial Results
- abrdn plc (SLFPY) Income Statement Analysis – Financial Results
Renalytix Plc (RTNXF)
About Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.29M | 3.40M | 2.97M | 1.49M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.13M | 2.70M | 2.05M | 804.00K | 74.00K | 30.99K | 0.00 |
| Gross Profit | 156.00K | 701.00K | 918.00K | 687.00K | -74.00K | -30.99K | 0.00 |
| Gross Profit Ratio | 6.82% | 20.60% | 30.91% | 46.08% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.29M | 14.30M | 14.65M | 10.04M | 4.57M | 39.60M | 0.00 |
| General & Administrative | 19.75M | 43.06M | 12.95M | 8.37M | 11.08M | 6.54M | 1.25M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -836.00K |
| SG&A | 19.75M | 43.06M | 12.95M | 8.37M | 11.08M | 6.54M | 418.00K |
| Other Expenses | 249.00K | 656.00K | 30.69M | 14.88M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.04M | 43.06M | 58.29M | 33.30M | 11.08M | 6.54M | 418.00K |
| Cost & Expenses | 31.17M | 45.76M | 60.34M | 34.10M | 11.08M | 6.54M | 418.00K |
| Interest Income | 0.00 | 509.00K | 12.00K | 236.00K | 530.00K | 39.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 2.00K | 3.00K | 2.00K | 20.00K | 0.00 |
| Depreciation & Amortization | 364.00K | 508.00K | 489.00K | 282.00K | 74.00K | 31.00K | 1.25M |
| EBITDA | -28.52M | -41.71M | -52.69M | -33.69M | -11.08M | -5.37M | -418.00K |
| EBITDA Ratio | -1,028.48% | -1,043.11% | -1,518.89% | -2,643.26% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.61M | -42.36M | -57.37M | -32.61M | -11.08M | -6.54M | -418.00K |
| Operating Income Ratio | -1,293.49% | -1,244.64% | -1,931.72% | -2,187.19% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.84M | -3.38M | 7.93M | -2.11M | -295.00K | 535.00K | 0.00 |
| Income Before Tax | -33.45M | -46.22M | -49.63M | -35.79M | -10.61M | -6.52M | -418.00K |
| Income Before Tax Ratio | -1,461.42% | -1,358.24% | -1,670.98% | -2,400.27% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00K | 2.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -33.46M | -45.61M | -45.28M | -34.73M | -9.84M | -42.30M | -1.25M |
| Net Income Ratio | -1,461.60% | -1,340.20% | -1,524.44% | -2,328.97% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.55 | -0.62 | -0.49 | -0.17 | -0.99 | -0.03 |
| EPS Diluted | -0.31 | -0.55 | -0.67 | -0.49 | -0.17 | -0.99 | -0.03 |
| Weighted Avg Shares Out | 108.18M | 82.21M | 67.98M | 70.87M | 57.91M | 42.56M | 41.80M |
| Weighted Avg Shares Out (Dil) | 108.18M | 82.21M | 73.84M | 71.48M | 59.08M | 42.56M | 41.80M |
Source: https://incomestatements.info
Category: Stock Reports